1. А.Н.Богдан, П.В.Морозов, Ю.В.Сейку. Ноотропные препараты в комплексной патогенетически обоснованной терапии депрессий (обзор литературы). Психиатрические расстройства в общей медицине. 2011; 3–4.
2. Boado RJ. In vivo upregulation of the bloodbrain barrier GLUT1 glucose transporter by brainderived peptides. Europ
J Neurol 1999; 6 (Suppl. 3): 37.
3. Francis-Turner L, Valouskova V, Morky J. Longterm effect of NGF, bFGF and Cerebrolysin on the spatial memory after fimbriafornix lesion in rats. J Neural Trasm 1996; 47 (Suppl.): 277.
4. Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm 2001; 108: 459–73.
5. Satou T, Imano M, Akai F et al. Morphological observation of effects of Cerebrolysin on cultured neural cells. Adv Biosci 1993; 87: 195–6.
6. Windisch M, Gschanes A, Hutter-Paier B. Neurotrophic activities and therapeutic experience with brain derived peptide preparation. J Neural Transm 1998; 53 (Suppl.): 289–98.
7. Francis-Turner L, Valouskova V. Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbriafornix transection: shortterm study. Neurosci Lett 1996; 202: 193–6.
8. Boado RJ. Brainderived peptides regulate the steady state levels and increase stability of the bloodbrain barrier GLUT1 glucose transporter mRNA. Neurosci Lett 1995; 197 (3): 179–82.
Авторы
О.В.Воробьева
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова